Welcome to our dedicated page for Maravai Lifesciences Holdings news (Ticker: MRVI), a resource for investors and traders seeking the latest updates and insights on Maravai Lifesciences Holdings stock.
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) is a life sciences company that regularly issues news and updates related to its role as a global provider of life science reagents and services. This news page aggregates announcements about Maravai’s financial performance, strategic initiatives, collaborations, and leadership changes, giving investors and researchers a focused view of developments that affect the MRVI stock and the company’s operating outlook.
Maravai’s news flow often centers on quarterly financial results, where the company reports revenue, net loss, segment performance for Nucleic Acid Production and Biologics Safety Testing, and non-GAAP metrics such as Adjusted EBITDA and Adjusted Net Loss. These releases typically include management commentary on trends in base business revenue, demand for nucleic acid products, and growth in biologics safety testing offerings such as host cell protein kits and MockV viral clearance kits.
In addition to earnings releases, Maravai publishes updates on organizational restructuring and cost reduction initiatives, including workforce reductions and efforts to align its cost structure with its current scale. The company also announces leadership transitions, such as the appointment of a new Chief Executive Officer and Chief Financial Officer, along with related governance and board changes documented in Form 8-K filings.
Another key area of MRVI news involves partnerships and agreements through Maravai’s TriLink BioTechnologies business. Recent announcements include license and supply agreements for TriLink’s CleanCap mRNA capping technology with partners that integrate this technology into RNA production platforms, as well as memoranda of understanding to collaborate on mRNA-based vaccine development and promote equitable access to vaccines in low- and middle-income countries.
Visitors to this page can review Maravai’s conference call and webcast notices, investor conference participation, and other corporate communications that provide context on the company’s strategic focus in nucleic acid technologies, mRNA tools, and biologics safety testing.
Maravai LifeSciences (NASDAQ: MRVI) will announce fourth quarter and full year 2025 financial and operating results after market close on Wednesday, February 25, 2026. The company will host a conference call and webcast the same day at 2:00 p.m. PT / 5:00 p.m. ET.
Dial-in numbers are 1-800-343-4136 or 1-203-518-9843 with Conference ID: MARAVAI. A live and archived webcast will be available in the Investors section at https://investors.maravai.com.
Maravai LifeSciences (NASDAQ: MRVI) will participate in investor conferences in November 2025 with CFO Raj Asarpota presenting via fireside chats. Dates/times: November 12, 2025 at 10:00 a.m. EST at the Stifel Healthcare Conference in New York, and November 19, 2025 at 10:00 a.m. GMT at the Jefferies Healthcare Conference in London.
A live webcast of each presentation will be available on the company’s Investor Relations website under News & Events, IR Calendar, and archived recordings will be posted after each event.
Maravai LifeSciences (NASDAQ: MRVI) reported third quarter 2025 results for the period ended September 30, 2025: revenue $41.6M, net loss $(45.1)M, and Adjusted EBITDA $(10.8)M. Nucleic Acid Production revenue was $25.4M (down 52.9% YoY) driven by a lack of high-volume CleanCap commercial vaccine orders, while Biologics Safety Testing revenue was $16.3M (up 7.2% YoY).
The company reiterated full-year 2025 revenue guidance of approximately $185.0M and said TriLink is expected to deliver double-digit sequential revenue growth in Q4 2025; management noted restructuring and cost-reduction initiatives are on track.
Maravai LifeSciences (NASDAQ: MRVI) will announce third quarter 2025 financial and operating results after market close on Thursday, November 6, 2025. The company will host an earnings conference call and webcast the same day at 2:00 p.m. PT / 5:00 p.m. ET.
Investors may join by phone at (800) 579-2543 or (785) 424-1789 using Conference ID: MARAVAI, or listen via live or archived webcast at https://investors.maravai.com.
Maravai LifeSciences (NASDAQ: MRVI) reported challenging Q2 2025 financial results with revenue declining 31.7% year-over-year to $47.4 million. The company posted a net loss of $(69.8) million, including a $30.4 million goodwill impairment, and negative Adjusted EBITDA of $(10.4) million.
Under new leadership with CEO Bernd Brust and CFO Raj Asarpota, Maravai announced a major restructuring targeting over $50 million in annualized cost savings through labor, facilities, and productivity initiatives. The base business excluding high-volume CleanCap grew 5%, driven by Cygnus products and Biologics Safety Testing segment growth of 9.9%.
The company has withdrawn its 2025 guidance as the new management team conducts a comprehensive business review, with expectations for Net Loss Reduction, Positive Adjusted EBITDA and Free Cash Flow by second half 2026.
Maravai LifeSciences (NASDAQ: MRVI), a global provider of life science reagents and services, has scheduled its second quarter 2025 financial results announcement for Monday, August 11, 2025, after market close.
The company will host a conference call and webcast at 2:00 p.m. PT/ 5:00 p.m. ET on the same day. Investors can join via phone by dialing (800) 267-6316 or (203) 518-9783 with Conference ID MARAVAI, or access the webcast through the "Investors" section of Maravai's website.
Maravai LifeSciences (NASDAQ: MRVI) has appointed Rajesh "Raj" Asarpota as Executive Vice President and Chief Financial Officer, effective June 30, 2025. He succeeds Kevin Herde, who will transition to an advisory role to support the transition.
Asarpota brings nearly three decades of executive leadership experience, including over 10 years as CFO in life sciences and medical device companies. He will lead Maravai's global Finance, Accounting, Treasury, Investor Relations, Corporate Strategy, and Information Technology teams, focusing on driving growth and profitability in nucleic acid technologies and bioprocess impurity analytics.
This CFO transition follows the recent appointment of Bernd Brust as CEO. The company will review its full-year 2025 financial guidance during its second-quarter earnings call in August.
Maravai LifeSciences (NASDAQ: MRVI) has released its 2024 Sustainability Report, highlighting significant progress across four key areas: Product Innovation, People, Governance, and Sustainable Growth. The company launched 49 new products and completed a state-of-the-art GMP facility in San Diego, increasing mRNA production capacity tenfold. Notable achievements include establishing an RNA Innovation Center with Johns Hopkins University and manufacturing over 130 GMP batches for mRNA.
The company demonstrated strong employee engagement with a 95% participation rate in their annual survey and expanded their employee resource programs. In governance, they appointed R. Andrew Eckert as independent Chairman and strengthened their intellectual property position. Sustainability initiatives included enhanced greenhouse gas emissions reporting and renewable energy projects, with their Leland facility's solar panels generating over 180,000 kWh.